Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The NIHR has produced a video highlighting the role that Clinical Trials Units (CTUs) play in developing an NIHR funding application, explaining both the role and benefits of working with CTUs. One of our co-directors, Professor Sallie Lamb is one of the CTU directors talking about the role of a CTU.

CTUs are specialist units which have been set up with a specific remit to design, conduct, analyse and publish clinical trials. They bring together a range of trials expertise within one centre, working in a collaborative relationship with Principal Investigators in order to deliver high quality and efficient clinical trials.

The NIHR recognises the important role of CTUs and researchers are strongly encouraged to contact a CTU early in the process of developing research ideas and preparing funding applications. Since 2008 the NIHR has provided UKCRC registered CTUs in England with the opportunity to apply for funding to increase their capacity to support NIHR funded projects and funding applications.

Professor Jim Thornton is Professor of Obstetrics and Gynaecology at the University of Nottingham and an experienced trialist. He was interviewed in the video and tells us that: “Success breeds success, and trials done with CTUs tend to be successful and therefore you get more funding for your next project…if you run one trial successfully the funders, researchers and trials units want to work with you in the future”.

Similar stories

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Emergency departments to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.